Travere Therapeutics (TVTX) EBT (2011 - 2026)
Travere Therapeutics (TVTX) posted EBT of -$36.7 million for Q1 2026, down 74.33% on a QoQ basis from -$21.1 million in Q4 2025, and up 10.84% year-over-year from -$33.1 million in Q1 2025.
Travere Therapeutics (TVTX) EBT (2011 - 2026) Analysis & Trends
Travere Therapeutics' EBT history runs 16 years deep, the most recent figure standing at -$36.7 million for Q1 2026.
- Quarterly EBT rose 10.84% year-over-year to -$36.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.8 million (up 80.17% YoY) and the FY2025 annual result came in at -$49.3 million, up 84.63% from the prior year.
- EBT was -$36.7 million for Q1 2026 at Travere Therapeutics, down from -$21.1 million in the prior quarter.
- Across five years, EBT topped out at $25.7 million in Q3 2025 and bottomed at -$135.8 million in Q1 2024.
- A 5-year average of -$65.5 million and a median of -$80.0 million in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT slumped 135.75% — and 2025, when it jumped 146.89%.
- Travere Therapeutics' EBT stood at -$85.6 million in 2022, then slipped by 3.45% to -$88.5 million in 2023, then surged by 31.84% to -$60.3 million in 2024, then jumped by 65.09% to -$21.1 million in 2025, then sank by 74.33% to -$36.7 million in 2026.
- Business Quant data shows TVTX's EBT at -$36.7 million in Q1 2026, -$21.1 million in Q4 2025, and $25.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.31 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 259.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 438.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Travere Therapeutics | 5.25 Bn | 5.25 Bn | 125.25 Mn | -36.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.72 Mn |
| Dec 31, 2025 | -21.07 Mn |
| Sep 30, 2025 | 25.71 Mn |
| Jun 30, 2025 | -12.74 Mn |
| Mar 31, 2025 | -41.19 Mn |
| Dec 31, 2024 | -60.34 Mn |
| Sep 30, 2024 | -54.84 Mn |
| Jun 30, 2024 | -69.57 Mn |
| Mar 31, 2024 | -135.77 Mn |
| Dec 31, 2023 | -88.53 Mn |
| Sep 30, 2023 | -89.23 Mn |
| Jun 30, 2023 | -101.87 Mn |
| Mar 31, 2023 | -96.49 Mn |
| Dec 31, 2022 | -85.57 Mn |
| Sep 30, 2022 | -83.92 Mn |
| Jun 30, 2022 | -79.97 Mn |
| Mar 31, 2022 | -81.69 Mn |
| Dec 31, 2021 | -88.77 Mn |
| Sep 30, 2021 | -35.60 Mn |
| Jun 30, 2021 | -38.96 Mn |